Reply

Macchia, Alejandro; Grancelli, Hugo; Varini, Sergio; Nul, Daniel; Laffaye, N; Mariani, Javier; Ferrante, Daniel; Badra, Raúl; Figal, J.; Ramos, Silvina; Tognoni, Gianni; Doval, Hernán C.

doi:10.1016/j.jacc.2013.03.024

Cited by 3 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…692,693 Similarly, polyunsaturated fatty acids failed to show convincing benefit. 241,[694][695][696][697][698] The role of aldosterone antagonists in the management of AF has not been extensively investigated in humans; although preliminary evidence from trials of eplerenone is encouraging for primary prevention, 243 at present there is no robust evidence to make any recommendation for the use of aldosterone antagonists for secondary prevention of AF. In patients where thrombus is identified on TOE, effective anticoagulation is recommended for at least 3 weeks I C…”

Section: Antiarrhythmic Effects Of Non-antiarrhythmic Drugsmentioning

confidence: 99%

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Benussi²,

et al. 2016

View full text Add to dashboard Cite

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.When citing, please reference the published version. Take down policyWhile the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

show abstract

Section: Antiarrhythmic Effects Of Non-antiarrhythmic Drugsmentioning

confidence: 99%

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Benussi²,

et al. 2016

View full text Add to dashboard Cite

show abstract

“…La Argentina no escapa de esta asociación entre la deprivación económica y social y la muerte prematura. (2,3) Sin embargo, el impacto que genera la desigualdad económica sobre la muerte a temprana edad entre las distintas zonas de la Argentina no se ha documentado suficientemente. Esta documentación debería tener consecuencias para la planificación sanitaria a fin, entre otras cosas, de priorizar intervenciones en aquellos segmentos de la población que se muestran más vulnerables.…”

Section: Introductionunclassified

Inequidad social, lugar de residencia y muerte prematura por cualquier causa en la Argentina

Macchia¹,

Mariani²,

Nul³

et al. 2016

Rev Argent Cardiol

View full text Add to dashboard Cite

Introducción: Aunque recientemente se reportó la relación entre la muerte prematura y la condición socioeconómica en la Argentina, no existen análisis sobre el impacto que dicha condición tiene en distintas regiones del país. Objetivo: Describir el impacto que la condición socioeconómica presentó sobre la incidencia de muerte prematura en las distintas provincias de la Argentina durante el período 2000-2010. Material y métodos: Se utilizó un modelo ecológico, que evaluó las tasas estandarizadas de muerte prematura (≤ 74 años) durante el período 2000-2010. Asimismo, se examinó la relación entre la condición socioeconómica medida en deciles de necesidades básicas insatisfechas por departamento geográfico y la muerte prematura. La unidad de análisis fueron los 512 departamentos de la Argentina y las 15 comunas de la ciudad de Buenos Aires. Resultados: La condición socioeconómica estuvo significativamente asociada con la muerte prematura en la Argentina durante el período analizado. En todas las provincias y regiones se observó un gradiente lineal entre la muerte precoz y la condición socioeconómica. Sin embargo, la pendiente de desigualdad entre los componentes de la condición socioeconómica varió significativamente entre los distintos departamentos. Mientras que en toda la Argentina la diferencia absoluta en la tasa estandarizada de muerte prematura entre los componentes extremos de condición socioeconómica fue de 10 muertes (rango: 7,81-12,36) por cada 10.000 personas por año, en la ciudad de Buenos Aires esa diferencia fue de 61 muertes (rango: 53-69). Las comunas del sur de la ciudad de Buenos Aires fueron las zonas con mayor desigualdad social y sanitaria de la Argentina. Conclusiones: Aunque la inequidad social tuvo un impacto significativo en la muerte prematura en todo el período en toda la Argentina, la ciudad de Buenos Aires se mostró como la región más desigual.

show abstract

“…Results of previous randomized controlled trials do not support that omega-3 fatty acids reduce the risk of recurrent atrial fibrillation (AF) in patients with AF (Kowey et al, 2010;Macchia et al, 2013;Nigam et al, 2014;Darghosian et al, 2015). There is also no support for reducing the risk of AF after cardiothoracic surgery (Heidarsdottir et al, 2010;Saravanan et al, 2010;Mozaffarian et al, 2012;Sandesara et al, 2012;Joss et al, 2017).…”

Section: Arrhythmiamentioning

confidence: 99%

“…It should be noted that omega-3 fatty acids may increase the risk of AF. Although previous randomized controlled studies have suggested that omega-3 fatty acids have no effect on the risk of recurrent AF or stroke in patients with AF (Mozaffarian et al, 2012;Sandesara et al, 2012;Macchia et al, 2013). However, studies assessing cardiovascular outcomes, such as REDUCE-IT, have found an increased risk of AF (Bhatt et al, 2019).…”

Section: Recommendations For Omega-3 Fatty Acids In Hypertriglyceride...mentioning

confidence: 99%

Role of omega-3 fatty acids in the prevention and treatment of cardiovascular Diseases: A consensus statement from the Experts’ Committee Of National Society Of Cardiometabolic Medicine

Dou

Zhou

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Low-density lipoprotein cholesterol (LDL-C) has been considered as the primary target for the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, there are still residual cardiovascular risks in some patients even if LDL-C achieves the target level. Emerging evidence suggestes that elevated triglyceride (TG) level or triglyceride-rich lipoprotein (TRL) cholesterol (TRL-C) is one of the important components of the residual cardiovascular risks. Omega-3 fatty acids have been shown to be one of the effective drugs for reducing TG. However, its efficacy in reducing the risk of ASCVD is inconsistent in large randomized clinical trials. There is lack of consensus among Experts regarding the application of omega-3 fatty acids in cardiovascular diseases including heart failure, arrhythmia, cardiomyopathy, hypertension, and sudden death. Hence, the current consensus will comprehensively and scientifically present the detailed knowledge about the omega-3 fatty acids from a variety of aspects to provide a reference for its management of omega-3 fatty acids application in the Chinese population.

show abstract

Reply

Cited by 3 publications

References 5 publications

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Inequidad social, lugar de residencia y muerte prematura por cualquier causa en la Argentina

Role of omega-3 fatty acids in the prevention and treatment of cardiovascular Diseases: A consensus statement from the Experts’ Committee Of National Society Of Cardiometabolic Medicine

Contact Info

Product

Resources

About